Clinical Hemorheology Research Articles

2nd Joint Meeting of the The European Society for Clinical Hemorheology and Microcirculation The International Society for Clinical Hemorheology The International Society of Biorheology July 4-7, 2021.

2nd Joint Meeting of the The European Society for Clinical Hemorheology and Microcirculation The International Society for Clinical Hemorheology The International Society of Biorheology July 4-7, 2021.

Identifying and analyzing the effects of electric fields on erythrocyte sedimentation rate.

Introduction: The influence of electric field on the nature of blood flow and cells is controversial. Erythrocytes sedimentation rate (ESR) examination is a recommended approach to diagnose a few health conditions such as polymyalgia rheumatic and temporal arteritis. Aim: In this study, we aimed to evaluate the effect of electric field on ESR of human male and female blood samples. Method: Healthy blood samples were exposed with electric field (in-vitro) with various exposure intensities. The Westergren method used to examine ESR in-vitro. Results: An increase of ESR was shown in blood samples of both genders at low to high exposure intensities. Female blood samples got a higher ESR than that of male blood samples at low exposure filed. However, that trend turned to opposite at high exposure electric field. Compare to untreated blood samples, the largest rate of ERS variation, for male and female blood samples, were about 140% versus a 135% respectively due to 72 V/m of exposure. Conclusion: Consequently, electric field produces an influence on the blood red cells sedimentation depending on the exposure intensity. References ALI, F. M., S. MOHAMED, W. & MOHAMED, M. R. 2003. Effect of 50 Hz, 0.2 mT magnetic fields on RBC properties and heart functions of albino rats. Bioelectromagnetics: Journal of the Bioelectromagnetics Society, The Society for Physical Regulation in Biology and Medicine, The European Bioelectromagnetics Association, 24, 535-545. BASKURT, O. K. & MEISELMAN, H. J. 2013. Erythrocyte aggregation: basic aspects and clinical importance. Clinical hemorheology and microcirculation, 53, 23-37. BRIGDEN, M. L. 1999. Clinical utility of the erythrocyte sedimentation rate. American family physician, 60, 1443-1450. FERNANDES, H. P., CESAR, C. L. & BARJAS-CASTRO, M. D. L. 2011. Electrical properties of the red blood cell membrane and immunohematological investigation. Revista brasileira de hematologia e hemoterapia, 33, 297-301. IINO, M. 1997. Effects of a homogeneous magnetic field on erythrocyte sedimentation and aggregation. Bioelectromagnetics: Journal of the Bioelectromagnetics Society, The Society for Physical Regulation in Biology and Medicine, The European Bioelectromagnetics Association, 18, 215-222. JUUTILAINEN, J. & LAHTINEN, T. 1985. Effects of low frequency electric fields on the sedimentation rate of human blood. Preliminary observations. International journal of biometeorology, 29, 243-252. KIZILOVA, N., BATYUK, L. & BARANETS, V. Human red blood cell properties and sedimentation rate: a biomechanical study. The International Conference of the Polish Society of Biomechanics, 2018. Springer, 3-22. MUSTAFA, B. T., YABA, S. & ISMAIL, A. H. Impacts of In Vivo Exposure Static Magnetic Field to Blood Viscosity. Materials Science Forum, 2020a. Trans Tech Publ, 369-378. MUSTAFA, B. T., YABA, S. P. & ISMAIL, A. H. 2020b. Influence of the static magnetic field on red blood cells parameters and platelets using tests of CBC and microscopy images. Biomedical Physics & Engineering Express, 6, 025004. MUSTAFA, B. T., YABA, S. P. & ISMAIL, A. H. 2019. A review of the Effects of Magnetic Field on main blood cells: in vivo and in vitro experiments. ZANCO Journal of Pure and Applied Sciences, 31, 40-50. SOX JR, H. C. & LIANG, M. H. 1986. The erythrocyte sedimentation rate. Guidelines for rational use. Annals of internal medicine, 104, 515-523. VENNAPUSA, B., DE LA CRUZ, L., SHAH, H., MICHALSKI, V. & ZHANG, Q.-Y. 2011. Erythrocyte sedimentation rate (ESR) measured by the Streck ESR-Auto Plus is higher than with the Sediplast Westergren method: a validation study. American journal of clinical pathology, 135, 386-390. YAMAGISHI, A. 1990. Biological systems in high magnetic field. Journal of magnetism and magnetic materials, 90, 43-46.

A Comprehensive Review of Vaccines against Covid-19

A Comprehensive Review of Vaccines against Covid-19

Клинические примеры применения фактора VIII свертывания крови с фактором Виллебранда у рожениц с III типом болезни Виллебранда

Болезнь Виллебранда (БВ) может представлять определенные трудности у рожениц с данной патологией. Приведены 2 клинических примера использования у женщин с БВ фактора VIII свертывания крови с фактором Виллебранда, показана эффективность и безопасность их применения. У одной пациентки было также показано использование фактора свертывания крови VIII с фактором Виллебранда во время экстракорпорального оплодотворения. Von Willebrand disease presents a certain hemostatic problem among parturients. This article shows the effectiveness and safety of using coagulation factor VIII with von Willebrand factor for the prevention of bleeding in childbirth in 2 patients with type 3 von Willebrand disease. In one patient, the use of coagulation factor VIII with von Willebrand factor during in vitro fertilization was also shown.

COVID-19 Sepsis and Microcirculation Dysfunction.

The spreading of Coronavirus (SARS-CoV-2) pandemic, known as COVID-19, has caused a great number of fatalities all around the World. Up to date (2020 May 6) in Italy we had more than 28,000 deaths, while there were more than 205.000 infected. The majority of patients affected by COVID-19 complained only slight symptoms: fatigue, myalgia or cough, but more than 15% of Chinese patients progressed into severe complications, with acute respiratory distress syndrome (ARDS), needing intensive treatment. We tried to summarize data reported in the last months from several Countries, highlighting that COVID-19 was characterized by cytokine storm (CS) and endothelial dysfunction in severely ill patients, where the progression of the disease was fast and fatal. Endothelial dysfunction was the fundamental mechanism triggering a pro-coagulant state, finally evolving into intravascular disseminated coagulation, causing embolization of several organs and consequent multiorgan failure (MOF). The Italian Society of Clinical Hemorheology and Microcirculation was aimed to highlight the role of microcirculatory dysfunction in the pathogenetic mechanisms of COVID-19 during the spreading of the biggest challenges to the World Health.

The Effect of Ginkgo Biloba Dropping Pills on Hemorheology and Blood Lipid: A Systematic Review of Randomized Trials.

Objective A systematic review of randomized trials was performed to assess the effect of Ginkgo Biloba Dropping Pills (GBDP) on clinical hemorheology and blood lipid indicators. Methods The data of the Embase, Cochrane Library, PubMed, Clinical Trials, China National Knowledge Infrastructure, the Wanfang database, the VIP database, and the Sinomed were retrieved by computers from the establishment of the database to March 27, 2018, and screened and extracted by two researchers according to inclusion and exclusion criteria. Cochrane 5.0 recommended bias risk assessment tool was used to evaluate the methodological quality of the included literature, and Revman 5.3 software were used for meta-analysis. Results 10 literatures were finally selected in accordance with the standard. There were a total of 1201 cases, 608 cases in ginkgo biloba dropping pill group and 593 in routine treatment group. Compared with control group, GBDP significantly improved plasma viscosity [N=383, RR= - 0.45, 95%CI=(-0.86,-0.04), P=0.03], whole blood high shear [N=232, RR= - 0.92,95%CI=(-1.69, -0.16), P =0.02], whole blood low shear [N = 232, RR = - 2.22, 95% CI = (- 3.74, -0.7), P = 0.004], red blood cell specific volume [N =132, RR = - 4.55, 95% CI = (- 6.36, 2.73), P < 0.000 01], fibrinogen [N=243, RR=-0.60,95%CI=(-0.82,-0.39), P<0.00001], triglyceride [N=912, RR=-0.60,95%CI=(-1.12, -0.07), P =0.03], cholesterol [N=912, RR=-0.97,95%CI=(-1.41, -0.52), P <0.0001], low-density cholesterol [N=1100, RR=-0.72,95%CI=(-1.19, -0.25), P =0.003], and sensitivity analysis before and after of high-density cholesterol [N=1020, RR=0.08,95%CI=(-0.17,0.34), P =0.52] and [N=683, RR=0.27,95%CI=(0.13,0.42), P =0.0003]. And seven adverse reactions were reported. Conclusion GBDP can improve hemorheology indexes, which is to reduce the blood viscosity, to improve blood lipid status, and to prevent and treat cardiocerebral and renal vascular diseases to a certain extent, with slight clinical adverse reactions. But our results were based on small amount of clinical studies with poor quality and insufficient evidence, which may lead to low credibility of conclusions. Therefore, more large-sample, multiple-center, randomized controlled clinical trials and related mechanisms researches are needed to obtain better clinical trial evidence in order to verify the further effectiveness and safety of GBDP on hemorheology.

Joint Meeting The European Society for Clinical Hemorheology and Microcirculation The International Society for Clinical Hemorheology The International Society of Biorheology Krakow, Poland July 2-6, 2018

Joint Meeting The European Society for Clinical Hemorheology and Microcirculation The International Society for Clinical Hemorheology The International Society of Biorheology Krakow, Poland July 2-6, 2018

Abstracts of Sixth Joint Meeting On Clinical Hemorheology, French Society of Biorheology, Society of Hemorheology of the West, Nevers, France 16, September 1988

Abstracts of Sixth Joint Meeting On Clinical Hemorheology, French Society of Biorheology, Society of Hemorheology of the West, Nevers, France 16, September 1988

ХАРАКТЕРИСТИКА МЕТОДА АГРЕГАТОСКОПИИ ДЛЯ РЕГИСТРАЦИИ МИКРОРЕОЛОГИИ ЭРИТРОЦИТОВ

Введение. Две микрореологические характеристики определяют кровоток в системе сосудов микроциркуляции — агрегация и деформируемость эритроцитов. В подавляющем большинстве приборов для регистрации агрегации эритроцитов (АЭ) отсутствует визуализация процесса, и интерпретация данных основывается на его косвенных характеристиках. Материалы и методы. Проведено исследование АЭ на созданной установке — агрегатоскопе, получены данные регистрации картины АЭ с последующей обработкой изображения с помощью специальной программы для ЭВМ. Информативность полученных данных была проверена в сравнительных исследованиях с использованием агрегометра эритроцитов Myrenne M1 и теста СОЭ. Результаты. Получены значительные положительные корреляции (r=0,90 и r=0,86, соответственно). Показано, что агрегатоскоп дает четкую картину изменения АЭ (ее снижение) при инкубации эритроцитов с хелатором Са2+ (ЭДТА, верапамил, изобутилметилксантин, монафрам). В ответ на инкубацию с препаратами другой группы, известными как стимуляторы АЭ (CaCl2, ионофор А23187, фенилэфрин, простагландин F2α), был получен достоверный прирост агрегации. Заключение. Метод агрегатоскопии в сочетании с программной обработкой изображений является удобным и надежным инструментом оценки суспензионной стабильности крови и точным методом измерения важной микрореологической характеристики эритроцитов — их агрегации. Introduction. Aggregation and deformability of erythrocytes are two microrheological characteristics that determine the blood fl ow in microcirculation vessels. In large majority of devices for registration of erythrocyte aggregation (EA) there is no visualization of the process, and the interpretation of the data is based on its indirect characteristics. Materials and methods. EA investigation was carried out on the created unit — aggregatoscop. Data were obtained for registration of EA followed by image processing using a special computer program. Data informativeness was verified in comparative studies using erythrocyte aggregometer Myrenne M1 and erythrocyte sedimentation rate test. Results. Significant positive correlations were obtained (r=0,90 and r=0,86, respectively). It was shown that aggregatoscop gave a clear picture of EA changes (its reduction) during erythrocytes incubation with Са2+ chelator (EDTA, verapamil, isobutylmethylxanthine, monaphram). Reliable increasing of aggregation was obtained in response to incubation with other agents — EA stimulants (CaCl2, ionophore A23187, phenylephrine, prostaglandin F2α). Conclusion. Aggregoscopy method in combination with software image processing is a convenient and reliable tool for assessing of blood suspension stability and an accurate method for measuring of important microrheological characteristics of erythrocytes — their aggregation.

History and future of hemorheology: From Reykjavik to Lisboa

The word "Biorheology" was introduced in 1948 during the first international congress on Rheology but "hemorheology" was first employed in 1951 during a meeting of the American Institute of Physics. Basically this science is related to physics and mechanics. The first international conference devoted to hemorheology was organized by AL Copley in Reykjavik (Iceland) in July 1969 and an International Society on Hemorheology was created. But after Reykjavik this society was named "International Society of Biorheology". The term "Clinical Hemorheology" was proposed in Nancy in 1979 which was named "First European Symposium on Clinical Hemorheology" and an European Coordinating Committee on Clinical Hemorheology (ECCCH) was created. The European Society on Clinical Hemorheology and Microcirculation was in fact created in Frankfurt in 1990 initiated by Albrecht Ehrly. In Nancy it was also decided to create a European Award named "Fahraeus Medal". After Nancy, the ECCCH and the European Society organized symposia in London, Baden Baden, Sienna, Frankfurt, Bordeaux, ... , Sofia ... and now Lisboa. Now it is necessary to give new directions for the development of Hemorheology and Clinical Hemorheology. Different ways can be considered:-Development of new theoretical models which take into account the heterogeneity of blood and blood vessel-Research on cell mechanobiology and mechanotransduction (leucocyte, endothelial and smooth muscle cells)-Study of cellular interactions (aggregation, adhesion, ...) and intracellular transport-Membrane rheology and concept of molecular fluidity-Dynamic blood coagulation in relation with molecular reactions-Development of metrology for clinical hemorheology.

Evidence-based hemorheology. Doesitexist?Applying evidence fromclinical studies to the individual patient.

Clinicians are used to treat individual patients, and therefore may feel that clinical trials and systematic reviews do not give information for optimal treatment of the single patient.Evidence Based Medicine (EBM) is the integration of research evidence (from clinically relevant studies conducted using sound methodology) with clinical expertise (clinician's cumulated experience) and patient values (personal preferences and unique concerns and expectations).The practical steps of EBM include: 1)assess the patient, 2)ask the clinical question, 3)acquire the evidence, 4)critically appraise the evidence, 5)apply the results to the patient and 6)self-evaluate one's practice.Clinical studies in clinical hemorheology include - among other - interventions in vascular medicine: coronary disease, stroke, peripheral vascular disease, venous insufficiency and thrombosis, etc.Of these, we will present some practical steps on how to apply therapy results of stroke studies to the individual patient (this addresses step number 5 in the previous definition of EBM practice).We will do this by discussing the differences between internal and external validity of clinical trials, and defining the importance of baseline risks to choose therapy using the data from the best and most useful studies available. In the end, clinicians will understand how to use evidence effectively.

Some surface phenomena in clinical hemorheology

Some surface phenomena in clinical hemorheology

Report on The 4th Meeting of the French Society on Clinical Haemorheology

Report on The 4th Meeting of the French Society on Clinical Haemorheology

Fourth European Conference on Clinical Haemorheology, Siena, Italy, 20–22 June 1985

Fourth European Conference on Clinical Haemorheology, Siena, Italy, 20–22 June 1985

Fourth Joint Meeting on Clinical Hemorheology, French Society of Biorheology, Society of Hemorheology of the West Chateaubriant de Bretagne, France 1 June 1985

Fourth Joint Meeting on Clinical Hemorheology, French Society of Biorheology, Society of Hemorheology of the West Chateaubriant de Bretagne, France 1 June 1985

Fifth European Conference on Clinical Hemorheology Bordeaux, France, 29 June–1 July 1987. Additional Abstracts1

Fifth European Conference on Clinical Hemorheology Bordeaux, France, 29 June–1 July 1987. Additional Abstracts1

Sixth European Conference on Clinical Hemorheology

Sixth European Conference on Clinical Hemorheology

Abstracts of papers presented at the 2nd European Conference On Clinical Hemorheology

Abstracts of papers presented at the 2nd European Conference On Clinical Hemorheology

The determination of blood viscoelasticity in clinical hemorheology

The determination of blood viscoelasticity in clinical hemorheology

Fåhraeus Award Lecture: The importance of rheological theory in clinical hemorheology

Fåhraeus Award Lecture: The importance of rheological theory in clinical hemorheology